A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses

Kaufmann, PA, Cortes, J, Awada, A et al. (8 more authors) (2013) A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. Onkologie: international journal for cancer research and treatment, 36 (Suppl 7). p. 97. ISSN 0378-584X

Metadata

Authors/Creators:
  • Kaufmann, PA
  • Cortes, J
  • Awada, A
  • Yelle, L
  • Perez, EA
  • Wanders, J
  • Olivo, M
  • He, Y
  • Ductus, C
  • Bischoff, J
  • Twelves, C
Dates:
  • Published: October 2013
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 06 Sep 2017 10:35
Last Modified: 06 Sep 2017 10:35
Status: Published
Publisher: S. Karger AG
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)